- Home
- VGZ vs TLSI Comparison
VGZ vs TLSI Comparison
Compare VGZ & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGZ
- TLSI
- Stock Information
- Founded
- VGZ 1983
- TLSI 2010
- Country
- VGZ United States
- TLSI United States
- Employees
- VGZ N/A
- TLSI N/A
- Industry
- VGZ
- TLSI Medical Specialities
- Sector
- VGZ
- TLSI Health Care
- Exchange
- VGZ Nasdaq
- TLSI Nasdaq
- Market Cap
- VGZ 171.5M
- TLSI 150.0M
- IPO Year
- VGZ N/A
- TLSI N/A
- Fundamental
- Price
- VGZ $2.18
- TLSI $4.60
- Analyst Decision
- VGZ Strong Buy
- TLSI Strong Buy
- Analyst Count
- VGZ 1
- TLSI 5
- Target Price
- VGZ $3.00
- TLSI $10.90
- AVG Volume (30 Days)
- VGZ 1.5M
- TLSI 102.3K
- Earning Date
- VGZ 10-22-2025
- TLSI 11-13-2025
- Dividend Yield
- VGZ N/A
- TLSI N/A
- EPS Growth
- VGZ N/A
- TLSI N/A
- EPS
- VGZ N/A
- TLSI N/A
- Revenue
- VGZ N/A
- TLSI $35,990,000.00
- Revenue This Year
- VGZ N/A
- TLSI $56.79
- Revenue Next Year
- VGZ N/A
- TLSI $54.15
- P/E Ratio
- VGZ N/A
- TLSI N/A
- Revenue Growth
- VGZ N/A
- TLSI 45.50
- 52 Week Low
- VGZ $0.47
- TLSI $3.42
- 52 Week High
- VGZ $2.46
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- VGZ 90.14
- TLSI 45.93
- Support Level
- VGZ $1.31
- TLSI $4.41
- Resistance Level
- VGZ $1.42
- TLSI $5.10
- Average True Range (ATR)
- VGZ 0.12
- TLSI 0.30
- MACD
- VGZ 0.08
- TLSI -0.07
- Stochastic Oscillator
- VGZ 79.04
- TLSI 20.59
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.